NewTherapiesSubgroup

GMMMG Greater Manchester Medicines Management Group

NHS

20th April 2010

Prucalopride (Resolor®▼) for use in for women in whom laxatives fail to provide adequate relief

The New Therapies Subgroup discussed the above drug at a meeting on 20th April 2010. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of prucalopride for the treatment of chronic constipation in women.

The group does not recommend the routine use of prucalopride. However it may be of use in women with chronic constipation where high doses of combined standard therapies have failed.

The group felt that whilst efficacy has been established against placebo, in practice it is unlikely that patients are offered no further treatment at all. In addition the cost effectiveness of the product has yet to be proven. If treatment with prucalopride treatment offsets the cost of hospital admissions then it may prove cost effective.

According to set criteria prucalopride was deemed to be a low priority for funding

Review date: April 2012

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.
▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drugreactions regardless of the severity of the reaction.